Ontvang nu dagelijks onze kooptips!
word abonnee
sluiten ✕
Terug naar discussie overzicht
H.D.L. schreef op 8 april 2019 10:44 :
Plus 8%?
Iemand?
Mogelijkheid: stuk in journal of hepatology - Elafibranor and nitazoxanide synergize to reduce fibrosis in a NASH modelwww.journal-of-hepatology.eu/article/...
Mogelijk een vertraagde reactie op de aankondiging van een ‘late breaker’ presentatie in Wenen later deze week.GENFIT Announces Upcoming Presentations on NASH, PBC and Diagnostics at the European Association for the Study of the Liver (EASL) International Liver Congress 2019 www.apnews.com/Globe%20Newswire/7aa08...
DeZwarteRidder schreef op 5 maart 2019 19:14 :
Intercept zal nog veel verder in elkaar storten.
NOG VERDER? Intercept Pharmaceuticals Inc NASDAQ: ICPT 120,40 USD +3,37 (2,88%)
Onderstaand een lezenswaardig artikel met daarin een nuancering van de resultaten van Viking. "Viking Therapeutics: Populations may vary In 2018, Viking Therapeutics thrilled investors with clinical trial data for VK2809, an experimental tablet that activates a thyroid hormone receptor known to help lower cholesterol, and only that receptor. Specificity is important from a safety perspective because activating a very similar receptor can lead to symptoms of hyperthyroidism. Viking licensed VK2809 from Ligand Pharmaceuticals thinking it could be a great new cholesterol-lowering therapy for patients who also have liver cells holding on to more lipids than necessary, or non-alcoholic fatty liver disease (NAFLD). During a 45-patient phase 2 study, people given VK2809 had significantly lower cholesterol, and that wasn't the only highlight. Viking Therapeutics stock soared last year because investigators noticed 90.9% of patients given VK2809 achieved liver fat reductions of 30% or greater compared to just 8.9% of the placebo group. Also, the average reduction was 59.7%, compared to baseline measurements taken 12 weeks earlier. Around a third of Americans have NAFLD, and an estimated 20 million have progressed to a state of chronic inflammation, or non-alcoholic steatohepatitis (NASH). There aren't any treatments for NASH, and it's quickly becoming the leading reason people need a new liver. It stands to reason that a treatment capable of lowering liver fat content should also stop inflammation, and Viking plans to begin a study with actual NASH patients in the second half of the year. A whopping 45.1% of Viking's float is sold short because there's a chance the results won't be much more impressive than another new drug candidate that works the same way. Not long before Viking thrilled the crowd, Madrigal Pharmaceuticals (NASDAQ: MDGL) shares spiked because its thyroid hormone receptor agonist, MGL-3196, helped 60% of NASH patients achieve liver fat reductions of 30% or better compared to 18.4% of the placebo group. While it looks like Viking's drug wiped the floor with Madrigal's, confident short-sellers are betting VK2809 won't look much better than MGL-3196 in the long run. That's because Madrigal's results come from a much larger study with biopsy-proven NASH patients that are much harder to treat than the 45 NAFLD patients enrolled in Viking's phase 2 trial."
Op Boursorama onderstaande gelezen: Een Bloomberg-analist suggereert dat Genfit, CimaBay en Viking overnamekandidaten kunnen zijn voor Gilead. "De waarderingen van deze 3 aandelen is tamelijk laag voor Gilead dat gemakkelijk meerdere acquisities aankan".www.boursorama.com/bourse/forum/1rPGN...
"Seven of nine patients getting Viking’s VK2809 at a dose of 5 milligrams once a day saw their liver fat cut by 50 percent or more. The biggest reduction in liver fat at the 5 milligram dose was 78 percent, according to data presented at the European Association for the Study of the Liver congress in Vienna. The company is also testing a 10 milligram dose. No serious side effects have been seen from the treatment to date." “There were no red flags” around liver safety and “cross-trial comparisons suggest that VK2809 has the better profile” compared to Madrigal Pharmaceuticals Inc.’s competing resmetirom, Bloomberg Intelligence analyst Michael Shah wrote in a note. finance.yahoo.com/news/viking-therape...
Dr. Bob schreef op 10 april 2019 08:21 :
Op Boursorama onderstaande gelezen:
Een Bloomberg-analist suggereert dat Genfit, CimaBay en Viking overnamekandidaten kunnen zijn voor Gilead. "De waarderingen van deze 3 aandelen is tamelijk laag voor Gilead dat gemakkelijk meerdere acquisities aankan".
www.boursorama.com/bourse/forum/1rPGN... Viking is inderdaad een zeer goede overnamekandidaat, Genfit bepaald niet.
GENFIT to Present Additional Positive Data from the Phase 2 Clinical Trial Evaluating Elafibranor in Primary Biliary Cholangitis at the International Liver Congress™ 2019 Lille (France), Cambridge (Massachusetts, United States), April 13, 2019 – GENFIT (Nasdaq and Euronext: GNFT - ISIN: FR0004163111), a late-stage biopharmaceutical company dedicated to the discovery and development of innovative therapeutic and diagnostic solutions in metabolic and liver related diseases, today announced it will present additional in depth analyses of data from its Phase 2 clinical trial evaluating elafibranor in PBC at the International Liver Congress™ (ILC) 2019. Elafibranor is GENFIT’s lead compound currently under evaluation in RESOLVE-IT, a Phase 3 clinical trial in NASH, and following the positive Phase 2 results in PBC, will be evaluated in a Phase 3 clinical trial for PBC, expected to initiate in 2019. The abstract describing Phase 2 PBC data was selected as “Best of ILC 2019” at this year’s conference.www.genfit.com/press-release/genfit-t...
DeZwarteRidder schreef op 11 april 2019 20:30 :
[...]
Viking is inderdaad een zeer goede overnamekandidaat, Genfit bepaald niet.
Na de waardedaling die volgde op het 'goede nieuws' lijkt Viking inderdaad een koopje.
Further analysis shows significant improvements in PBC cholestatic markers such as GGT (-39% for 80mg and -40% for 120mg), significant reduction on immuno/inflammation markers (eg. IgM, hsCRP), decrease in bile acid precursors (C4), and improvement in metabolic markers (total cholesterol, LDL, triglycerides) New data also suggest an improvement in pruritus – a major symptom of PBC – with a median change in VAS of -24% (80mg) and -49% (120mg) vs. -7% (placebo)www.globenewswire.com/news-release/20...
Brouya schreef op 13 april 2019 11:43 :
Further analysis shows significant improvements in PBC cholestatic markers such as GGT (-39% for 80mg and -40% for 120mg), significant reduction on immuno/inflammation markers (eg. IgM, hsCRP), decrease in bile acid precursors (C4), and improvement in metabolic markers (total cholesterol, LDL, triglycerides)
New data also suggest an improvement in pruritus – a major symptom of PBC – with a median change in VAS of -24% (80mg) and -49% (120mg) vs. -7% (placebo)
www.globenewswire.com/news-release/20... PBC is geen NASH. Het NASH-middel gaat duidelijk mislukken.
DeZwarteRidder schreef op 13 april 2019 12:56 :
[...]
PBC is geen NASH.
Het NASH-middel gaat duidelijk mislukken.
Dit is het GENFIT forum. Niet het NASH forum.
Brouya schreef op 13 april 2019 13:33 :
[...]
Dit is het GENFIT forum. Niet het NASH forum.
Dus Genfit heeft niks meer met NASH te maken....???
The abstract describing Phase 2 PBC data was selected as “Best of ILC 2019” at this year’s conference.www.globenewswire.com/news-release/20...
Brouya schreef op 13 april 2019 13:35 :
The abstract describing Phase 2 PBC data was selected as “Best of ILC 2019” at this year’s conference.
www.globenewswire.com/news-release/20... PBC is de enige kans voor Genfit.
Brouya schreef op 8 april 2019 22:01 :
[...]
NOG VERDER?
Intercept Pharmaceuticals Inc
NASDAQ: ICPT
120,40 USD +3,37 (2,88%)
Intercept ca 92 USD vandaag.
DeZwarteRidder schreef op 15 april 2019 16:43 :
[...]
Intercept ca 92 USD vandaag.
Beleggen gaat mij om geld verdienen. Dus op tijd winst nemen (in dit (Intercept) geval later ook weer instappen). Genfit hetzelfde, bij een mooie stijging verkopen en bij een flinke daling weer aankopen. Ik zal hier verder niet over uitweiden want is bij veel Biotech vanzelfsprekend tenzij je zoals jij niet belegd maar enkel aandacht zoekt op een forum.
seekingalpha.com/news/3450680-genfit-... Genfit (GNFT +3.5%) is up on below-average volume in reaction to additional data from a Phase 2 clinical trial evaluating lead drug elafibranor in patients with primary biliary cholangitis (PBC). The results were presented at The International Liver Congress in Vienna. Patients receiving the 80 mg and 120 mg doses experienced reductions in mean alkaline phosphatase (ALP) of 48% and 41%, respectively, compared to a 3% increase for placebo (elevated ALP is a biomarker for liver disease). Patients in the treatment groups also showed improvements in other PBC markers, including the enzyme GGT, total cholesterol, low-density lipoprotein and triglycerides. The company expects to launch a Phase 3 study in PBC this year. A Phase 3 in NASH is underway.
Brouya schreef op 16 april 2019 08:47 :
[...]
Beleggen gaat mij om geld verdienen. Dus op tijd winst nemen (in dit (Intercept) geval later ook weer instappen). Genfit hetzelfde, bij een mooie stijging verkopen en bij een flinke daling weer aankopen. Ik zal hier verder niet over uitweiden want is bij veel Biotech vanzelfsprekend tenzij je zoals jij niet belegd maar enkel aandacht zoekt op een forum.
Dus jij wil beweren dat jij de koersbewegingen van Intercept precies kon voorspellen....!!!???
Aantal posts per pagina:
20
50
100
Direct naar Forum
-- Selecteer een forum --
Koffiekamer
Belastingzaken
Beleggingsfondsen
Beursspel
BioPharma
Daytraders
Garantieproducten
Opties
Technische Analyse
Technische Analyse Software
Vastgoed
Warrants
10 van Tak
4Energy Invest
Aalberts
AB InBev
Abionyx Pharma
Ablynx
ABN AMRO
ABO-Group
Acacia Pharma
Accell Group
Accentis
Accsys Technologies
ACCSYS TECHNOLOGIES PLC
Ackermans & van Haaren
ADMA Biologics
Adomos
AdUX
Adyen
Aedifica
Aegon
AFC Ajax
Affimed NV
ageas
Agfa-Gevaert
Ahold
Air France - KLM
Airspray
Akka Technologies
AkzoNobel
Alfen
Allfunds Group
Allfunds Group
Almunda Professionals (vh Novisource)
Alpha Pro Tech
Alphabet Inc.
Altice
Alumexx ((Voorheen Phelix (voorheen Inverko))
AM
Amarin Corporation
Amerikaanse aandelen
AMG
AMS
Amsterdam Commodities
AMT Holding
Anavex Life Sciences Corp
Antonov
Aperam
Apollo Alternative Assets
Apple
Arcadis
Arcelor Mittal
Archos
Arcona Property Fund
arGEN-X
Aroundtown SA
Arrowhead Research
Ascencio
ASIT biotech
ASMI
ASML
ASR Nederland
ATAI Life Sciences
Atenor Group
Athlon Group
Atrium European Real Estate
Auplata
Avantium
Axsome Therapeutics
Azelis Group
Azerion
B&S Group
Baan
Ballast Nedam
BALTA GROUP N.V.
BAM Groep
Banco de Sabadell
Banimmo A
Barco
Barrick Gold
BASF SE
Basic-Fit
Basilix
Batenburg Beheer
BE Semiconductor
Beaulieulaan
Befimmo
Bekaert
Belgische aandelen
Beluga
Beter Bed
Bever
Binck
Biocartis
Biophytis
Biosynex
Biotalys
Bitcoin en andere cryptocurrencies
bluebird bio
Blydenstijn-Willink
BMW
BNP Paribas S.A.
Boeing Company
Bols (Lucas Bols N.V.)
Bone Therapeutics
Borr Drilling
Boskalis
BP PLC
bpost
Brand Funding
Brederode
Brill
Bristol-Myers Squibb
Brunel
C/Tac
Campine
Canadese aandelen
Care Property Invest
Carmila
Carrefour
Cate, ten
CECONOMY
Celyad
CFD's
CFE
CGG
Chinese aandelen
Cibox Interactive
Citygroup
Claranova
CM.com
Co.Br.Ha.
Coca-Cola European Partners
Cofinimmo
Cognosec
Colruyt
Commerzbank
Compagnie des Alpes
Compagnie du Bois Sauvage
Connect Group
Continental AG
Corbion
Core Labs
Corporate Express
Corus
Crescent (voorheen Option)
Crown van Gelder
Crucell
CTP
Curetis
CV-meter
CVC Capital Partners
Cyber Security 1 AB
Cybergun
D'Ieteren
D.E Master Blenders 1753
Deceuninck
Delta Lloyd
DEME
Deutsche Cannabis
DEUTSCHE POST AG
Dexia
DGB Group
DIA
Diegem Kennedy
Distri-Land Certificate
DNC
Dockwise
DPA Flex Group
Draka Holding
DSC2
DSM
Duitse aandelen
Dutch Star Companies ONE
Duurzaam Beleggen
DVRG
Ease2pay
Ebusco
Eckert-Ziegler
Econocom Group
Econosto
Edelmetalen
Ekopak
Elastic N.V.
Elia
Endemol
Energie
Energiekontor
Engie
Envipco
Erasmus Beursspel
Eriks
Esperite (voorheen Cryo Save)
EUR/USD
Eurobio
Eurocastle
Eurocommercial Properties
Euronav
Euronext
Euronext
Euronext.liffe Optiecompetitie
Europcar Mobility Group
Europlasma
EVC
EVS Broadcast Equipment
Exact
Exmar
Exor
Facebook
Fagron
Fastned
Fingerprint Cards AB
First Solar Inc
FlatexDeGiro
Floridienne
Flow Traders
Fluxys Belgium D
FNG (voorheen DICO International)
Fondsmanager Gezocht
ForFarmers
Fountain
Frans Maas
Franse aandelen
FuelCell Energy
Fugro
Futures
FX, Forex, foreign exchange market, valutamarkt
Galapagos
Gamma
Gaussin
GBL
Gemalto
General Electric
Genfit
Genmab
GeoJunxion
Getronics
Gilead Sciences
Gimv
Global Graphics
Goud
GrandVision
Great Panther Mining
Greenyard
Grolsch
Grondstoffen
Grontmij
Guru
Hagemeyer
HAL
Hamon Groep
Hedge funds: Haaien of helden?
Heijmans
Heineken
Hello Fresh
HES Beheer
Hitt
Holland Colours
Homburg Invest
Home Invest Belgium
Hoop Effektenbank, v.d.
Hunter Douglas
Hydratec Industries (v/h Nyloplast)
HyGear (NPEX effectenbeurs)
HYLORIS
Hypotheken
IBA
ICT Automatisering
Iep Invest (voorheen Punch International)
Ierse aandelen
IEX Group
IEX.nl Sparen
IMCD
Immo Moury
Immobel
Imtech
ING Groep
Innoconcepts
InPost
Insmed Incorporated (INSM)
IntegraGen
Intel
Intertrust
Intervest Offices & Warehouses
Intrasense
InVivo Therapeutics Holdings Corp (NVIV)
Isotis
JDE PEET'S
Jensen-Group
Jetix Europe
Johnson & Johnson
Just Eat Takeaway
Kardan
Kas Bank
KBC Ancora
KBC Groep
Kendrion
Keyware Technologies
Kiadis Pharma
Kinepolis Group
KKO International
Klépierre
KPN
KPNQwest
KUKA AG
La Jolla Pharmaceutical
Lavide Holding (voorheen Qurius)
LBC
LBI International
Leasinvest
Logica
Lotus Bakeries
Macintosh Retail Group
Majorel
Marel
Mastrad
Materialise NV
McGregor
MDxHealth
Mediq
Melexis
Merus Labs International
Merus NV
Microsoft
Miko
Mithra Pharmaceuticals
Montea
Moolen, van der
Mopoli
Morefield Group
Mota-Engil Africa
MotorK
Moury Construct
MTY Holdings (voorheen Alanheri)
Nationale Bank van België
Nationale Nederlanden
NBZ
Nedap
Nedfield
Nedschroef
Nedsense Enterpr
Nel ASA
Neoen SA
Neopost
Neovacs
NEPI Rockcastle
Netflix
New Sources Energy
Neways Electronics
NewTree
NexTech AR Solutions
NIBC
Nieuwe Steen Investments
Nintendo
Nokia
Nokia OYJ
Nokia Oyj
Novacyt
NOVO-NORDISK AS
NPEX
NR21
Numico
Nutreco
Nvidia
NWE Nederlandse AM Hypotheek Bank
NX Filtration
NXP Semiconductors NV
Nyrstar
Nyxoah
Océ
OCI
Octoplus
Oil States International
Onconova Therapeutics
Ontex
Onward Medical
Onxeo SA
OpenTV
OpGen
Opinies - Tilburg Trading Club
Opportunty Investment Management
Orange Belgium
Oranjewoud
Ordina Beheer
Oud ForFarmers
Oxurion (vh ThromboGenics)
P&O Nedlloyd
PAVmed
Payton Planar Magnetics
Perpetuals, Steepeners
Pershing Square Holdings Ltd
Personalized Nursing Services
Pfizer
Pharco
Pharming
Pharnext
Philips
Picanol
Pieris Pharmaceuticals
Plug Power
Politiek
Porceleyne Fles
Portugese aandelen
PostNL
Priority Telecom
Prologis Euro Prop
ProQR Therapeutics
PROSIEBENSAT.1 MEDIA SE
Prosus
Proximus
Qrf
Qualcomm
Quest For Growth
Rabobank Certificaat
Randstad
Range Beleggen
Recticel
Reed Elsevier
Reesink
Refresco Gerber
Reibel
Relief therapeutics
Renewi
Rente en valuta
Resilux
Retail Estates
RoodMicrotec
Roularta Media
Royal Bank Of Scotland
Royal Dutch Shell
RTL Group
RTL Group
S&P 500
Samas Groep
Sapec
SBM Offshore
Scandinavische (Noorse, Zweedse, Deense, Finse) aandelen
Schuitema
Seagull
Sequana Medical
Shurgard
Siemens Gamesa
Sif Holding
Signify
Simac
Sioen Industries
Sipef
Sligro Food Group
SMA Solar technology
Smartphoto Group
Smit Internationale
Snowworld
SNS Fundcoach Beleggingsfondsen Competitie
SNS Reaal
SNS Small & Midcap Competitie
Sofina
Softimat
Solocal Group
Solvac
Solvay
Sopheon
Spadel
Sparen voor later
Spectra7 Microsystems
Spotify
Spyker N.V.
Stellantis
Stellantis
Stern
Stork
Sucraf A en B
Sunrun
Super de Boer
SVK (Scheerders van Kerchove)
Syensqo
Systeem Trading
Taiwan Semiconductor Manufacturing Company (TSMC)
Technicolor
Tele Atlas
Telegraaf Media
Telenet Groep Holding
Tencent Holdings Ltd
Tesla Motors Inc.
Tessenderlo Group
Tetragon Financial Group
Teva Pharmaceutical Industries
Texaf
Theon International
TherapeuticsMD
Thunderbird Resorts
TIE
Tigenix
Tikkurila
TINC
TITAN CEMENT INTERNATIONAL
TKH Group
TMC
TNT Express
TomTom
Transocean
Trigano
Tubize
Turbo's
Twilio
UCB
Umicore
Unibail-Rodamco
Unifiedpost
Unilever
Unilever
uniQure
Unit 4 Agresso
Univar
Universal Music Group
USG People
Vallourec
Value8
Value8 Cum Pref
Van de Velde
Van Lanschot
Vastned
Vastned Retail Belgium
Vedior
VendexKBB
VEON
Vermogensbeheer
Versatel
VESTAS WIND SYSTEMS
VGP
Via Net.Works
Viohalco
Vivendi
Vivoryon Therapeutics
VNU
VolkerWessels
Volkswagen
Volta Finance
Vonovia
Vopak
Warehouses
Wave Life Sciences Ltd
Wavin
WDP
Wegener
Weibo Corp
Wereldhave
Wereldhave Belgium
Wessanen
What's Cooking
Wolters Kluwer
X-FAB
Xebec
Xeikon
Xior
Yatra Capital Limited
Zalando
Zenitel
Zénobe Gramme
Ziggo
Zilver - Silver World Spot (USD)
Premium
Word nu abonnee van IEX en krijg onbeperkt toegang tot onze (koop)tips en succesvolle modelportefeuilles. Nu 3 maanden voor slechts €19,95! Profiteer van 58% korting!
Word abonnee